Clinical Cardiology Alert – November 1, 2013
November 1, 2013
View Issues
-
Clinical Briefs in Primary Care
Evidence-based updates in primary care medicine By Louis Kuritzky, MD -
Pharmacology Watch: Evidence-based updates in clinical pharmacology
Medications for Risk Reduction of Breast Cancer in Women -
Preventive Angioplasty in Myocardial Infarction?
Primary percutaneous coronary intervention (PCI) is the optimal treatment for patients suffering ST-elevation myocardial infarction (STEMI). -
Is Cardioversion After Acute Atrial Fibrillation Safe Without Anticoagulation?
In clinical practice, patients with atrial fibrillation (AF) duration < 48 hours often undergo cardioversion without systemic anticoagulation. -
Dabigatran Not Safe For Prosthetic Heart Valves
Dabigatran is a novel anticoagulant that has been shown to be at least as good as warfarin at preventing thromboembolism in atrial fibrillation (AF). -
Stroke Risk from Pacemaker Leads in Patients with PFO
Pacemaker or defibrillator leads have been shown to have attached thrombi in up to one-third of cases and asymptomatic pulmonary emboli have been documented in up to 20% of patients. -
Is a Totally Subcutaneous ICD Safe and Effective?
Multiple prospective, randomized trials have shown a mortality reduction in patients with reduced left ventricular ejection fraction who undergo prophylactic implantable cardioverter-defibrillator (ICD) therapy.